Validating vs. WinNonlin... [🇷 for BE/BA]

posted by Helmut Homepage – Vienna, Austria, 2010-04-24 02:28 (5535 d 07:42 ago) – Posting: # 5208
Views: 62,586

Dear bears!

❝ Just like analyzing a replicate crossover. I can not find the results obtained from analyzing with WinNonlin using a linear mixed effects model. As far as I could remember, we got pretty similar results as with WinNonlin at that moment.


D. Labes referred to one of my old posts: WinNonlin's method (assuming equal variances) is flawed - even in the current releases WinNonlin 5.3 and Phoenix/WinNonlin 6.1. The model is equivalent to the common one-way ANOVA (but like everything in WinNonlin based on maximum likelihood); only one fixed effect = treatment (no random subject term whatsoever). A random subject term does not make sense IMHO.

❝ Which model is more appropriate for analyzing parallel BE study with R?


Agreeing with D. Labes in the top post I would also use a t-test for unequal variances. That's the default of t.test and in conformity with FDA's requirements. For simple code see the subsequent post in the quoted thread.

Dif-tor heh smusma 🖖🏼 Довге життя Україна! [image]
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

UA Flag
Activity
 Admin contact
23,424 posts in 4,927 threads, 1,675 registered users;
36 visitors (0 registered, 36 guests [including 9 identified bots]).
Forum time: 10:11 CEST (Europe/Vienna)

Philosophy, like medicine, has plenty of drugs, few good remedies,
and hardly any specific cures.    Sebastien-Roch Nicolas de Chamfort

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5